Literature DB >> 26166604

Myocardial Energy Substrate Metabolism in Heart Failure : from Pathways to Therapeutic Targets.

Arata Fukushima, Kenneth Milner, Abhishek Gupta, Gary D Lopaschuk1.   

Abstract

Despite recent advances in therapy, heart failure remains a major cause of mortality and morbidity and is a growing healthcare burden worldwide. Alterations in myocardial energy substrate metabolism are a hallmark of heart failure, and are associated with an energy deficit in the failing heart. Previous studies have shown that a metabolic shift from mitochondrial oxidative metabolism to glycolysis, as well as an uncoupling between glycolysis and glucose oxidation, plays a crucial role in the development of cardiac inefficiency and functional impairment in heart failure. Therefore, optimizing energy substrate utilization, particularly by increasing mitochondrial glucose oxidation, can be a potentially promising approach to decrease the severity of heart failure by improving mechanical cardiac efficiency. One approach to stimulating myocardial glucose oxidation is to inhibit fatty acid oxidation. This review will overview the physiological regulation of both myocardial fatty acid and glucose oxidation in the heart, and will discuss what alterations in myocardial energy substrate metabolism occur in the failing heart. Furthermore, lysine acetylation has been recently identified as a novel post-translational pathway by which mitochondrial enzymes involved in all aspects of cardiac energy metabolism can be regulated. Thus, we will also discuss the effect of acetylation of metabolic enzymes on myocardial energy substrate preference in the settings of heart failure. Finally, we will focus on pharmacological interventions that target enzymes involved in fatty acid uptake, fatty acid oxidation, transcriptional regulation of fatty acid oxidation, and glucose oxidation to treat heart failure.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26166604     DOI: 10.2174/1381612821666150710150445

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  32 in total

1.  PDE5 Inhibitor Tadalafil and Hydroxychloroquine Cotreatment Provides Synergistic Protection against Type 2 Diabetes and Myocardial Infarction in Mice.

Authors:  Rui Wang; Lei Xi; Rakesh C Kukreja
Journal:  J Pharmacol Exp Ther       Date:  2017-01-25       Impact factor: 4.030

Review 2.  The Modulating Effects of Cardiac Resynchronization Therapy on Myocardial Metabolism in Heart Failure.

Authors:  Yi-Zhou Xu; Chao-Feng Chen; Bin Chen; Xiao-Fei Gao; Wei Hua; Yong-Mei Cha; Petras P Dzeja
Journal:  Pacing Clin Electrophysiol       Date:  2016-12-07       Impact factor: 1.976

3.  Ketones Step to the Plate: A Game Changer for Metabolic Remodeling in Heart Failure?

Authors:  Stephen C Kolwicz; Sophia Airhart; Rong Tian
Journal:  Circulation       Date:  2016-01-27       Impact factor: 29.690

4.  Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes.

Authors:  A Aragón-Herrera; S Feijóo-Bandín; D Rodríguez-Penas; E Roselló-Lletí; M Portolés; M Rivera; M Bigazzi; D Bani; O Gualillo; J R González-Juanatey; F Lago
Journal:  Endocrine       Date:  2018-02-06       Impact factor: 3.633

Review 5.  Human-induced pluripotent stem cells for modelling metabolic perturbations and impaired bioenergetics underlying cardiomyopathies.

Authors:  Chrishan J A Ramachandra; Jasper Chua; Shuo Cong; Myu Mai Ja Kp; Winston Shim; Joseph C Wu; Derek J Hausenloy
Journal:  Cardiovasc Res       Date:  2021-02-22       Impact factor: 10.787

6.  Modelling Metabolic Shifts during Cardiomyocyte Differentiation, Iron Deficiency and Transferrin Rescue Using Human Pluripotent Stem Cells.

Authors:  Benjamin B Johnson; Johannes Reinhold; Terri L Holmes; Jamie A Moore; Verity Cowell; Andreia S Bernardo; Stuart A Rushworth; Vassilios Vassiliou; James G W Smith
Journal:  Metabolites       Date:  2021-12-22

7.  Successful metabolic adaptations leading to the prevention of high fat diet-induced murine cardiac remodeling.

Authors:  Nathan W Roberts; Magdalis González-Vega; Tirsit K Berhanu; Aaron Mull; Jesús García; Ahlke Heydemann
Journal:  Cardiovasc Diabetol       Date:  2015-09-25       Impact factor: 9.951

8.  Cancer-induced Cardiac Atrophy Adversely Affects Myocardial Redox State and Mitochondrial Oxidative Characteristics.

Authors:  David E Lee; Jacob L Brown; Megan E Rosa-Caldwell; Richard A Perry; Lemuel A Brown; Wesley S Haynie; Tyrone A Washington; Michael P Wiggs; Narasimhan Rajaram; Nicholas P Greene
Journal:  JCSM Rapid Commun       Date:  2020-08-07

Review 9.  Targeting Adrenergic Receptors in Metabolic Therapies for Heart Failure.

Authors:  Dianne M Perez
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

10.  Sirt1 improves heart failure through modulating the NF-κB p65/microRNA-155/BNDF signaling cascade.

Authors:  Bin Lin; Hui Zhao; Li Li; Zhenzhen Zhang; Nan Jiang; Xiaowei Yang; Tao Zhang; Bowen Lian; Yaokai Liu; Chi Zhang; Jiaxiang Wang; Feng Wang; Deguang Feng; Jing Xu
Journal:  Aging (Albany NY)       Date:  2020-11-18       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.